New study's big ask: Can amyloid clearing drugs halt Alzheimer's in high-risk patients?
This article was originally published in Scrip
The slight hint of efficacy seen in one of two Phase III clinical trials for Eli Lilly's solanezumab in patients with mild Alzheimer's disease will be put to the test alongside a Phase II Lilly small molecule and Roche's Phase III gantenerumab in a study by the Washington University School of Medicine in St Louis, Missouri to determine whether therapies targeting amyloid-beta can prevent Alzheimer's in people with genetic predispositions for the disease.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.